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Abstract We have investigated the extent and pattern
of immunostaining for ubiquitin protein (UBQ) in
60 patients with frontotemporal lobar degeneration
(FTLD) with ubiquitin-positive, tau-negative inclu-
sions (FTLD-U), 37 of whom were ascertained in
Manchester UK and 23 in Newcastle-Upon-Tyne, UK.
There were three distinct histological patterns accord-
ing to the form and distribution of the UBQ pathology.
Histological type 1 was present in 19 patients (32%)
and characterised by the presence of a moderate number,
or numerous, UBQ immunoreactive neurites and intran-
euronal cytoplasmic inclusions within layer II of the
frontal and temporal cerebral cortex, and cytoplasmic
inclusions within granule cells of the dentate gyrus;
neuronal intranuclear inclusions (NII) of a “cat’s eye”
or “lentiform” appearance were present in 17 of these
patients. In histological type 2 (16 patients, 27%),
UBQ neurites were predominantly, or exclusively,
present with few intraneuronal cytoplasmic inclusions
within layer II of the cerebral cortex, while in histologi-
cal type 3 (25 patients, 42%), UBQ intraneuronal cyto-
plasmic inclusions either within the cortical layer II or
in the granule cells of the dentate gyrus, with few or no
UBQ neurites, were seen. In neither of these latter two
groups were NII present. The inXuence of histological
type on clinical phenotype was highly signiWcant with
type 1 histology being associated clinically with cases of
frontotemporal dementia (FTD) or progressive non-
Xuent aphasia (PNFA), type 2 histology with semantic
dementia (SD), and type 3 histology with FTD, or FTD
and motor neurone disease (MND).
Introduction
Frontotemporal lobar degeneration (FTLD) is a
descriptive term that refers to a clinically and patholog-
ically heterogeneous group of non-Alzheimer forms of
dementia with onset of illness usually before 65 years
of age [21, 29]. While frontotemporal dementia (FTD)
is the main clinical syndrome arising from the degener-
ation of the frontal and temporal lobes in FTLD,
related disorders of semantic dementia (SD), progres-
sive non-Xuent aphasia (PNFA) stem from diVering (to
FTD) topographical distributions of similar underlying
pathologies [21, 29]. When the frontal and temporal
lobes are bilaterally aVected, the syndrome of FTD
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emerges, while in SD the temporal lobes are bilaterally
aVected and in PNFA the left cerebral hemisphere is
preferentially aVected [21, 29]. When the behavioural
and personality changes of FTD are accompanied by
clinical Motor Neurone Disease, the syndrome of
frontotemporal dementia with Motor Neurone Disease
(MND) (FTD + MND) emerges [21, 29].
There are also pathological heterogeneities within
FTLD. About 45% cases contain insoluble tau proteins
in their brains in the form of intraneuronal neuroWbril-
lary tangles or Pick bodies [28, 30]: many such cases are
associated with mutations in the tau (MAPT) gene (see
[19] for review). However, numerous pathological
investigations on large series of patients with FTLD [2,
6, 10–15, 17, 20, 28, 30] indicate that a tau-negative his-
tology is a frequent, if not the most common, change
underlying FTLD, with the great majority of cases
showing ubiquitin (UBQ)-positive pathology in the
form of intraneuronal inclusions and/or neuritic
changes in cerebral cortex and the hippocampus, a
pathology now referred to as FTLD-U or FTLD-MND
when clinical MND is also present. In some FTLD-U
cases, neuronal intranuclear inclusions of a “cat’s eye”
or “lentiform” appearance have been described [16,
32], especially in those cases with autosomal dominant
inheritance of disease and linkage to chromosome 17
[8, 18, 24, 25].
In this study, we have investigated the extent and
pattern of UBQ immunostaining in 60 patients with
FTLD, 37 of whom were ascertained in Manchester
UK, and 23 in Newcastle-Upon-Tyne, UK. We have
found three distinct patterns of UBQ staining, and
have correlated these with clinical phenotype and
MAPT haplotype.
Materials and methods
Thirty seven cases with FTLD-U or FTLD-MND were
selected for this present study from a series of 73 con-
secutive patients dying since 1987 within North West
region of United Kingdom, fulWlling clinical diagnostic
criteria for sporadic and familial FTLD [4, 23] (patients
#1–37, Table 1). We have recently described the histo-
pathological characteristics of these patients [17, 28].
Of these 37 patients, 25 (68%) were male, 12 (32%)
were female. Mean age at onset of disease was
57.7 § 7.5 years, and mean duration of illness was
8.1 § 4.2 years. A further 23 cases of pathologically
diagnosed FTLD-U were ascertained through the
Brain Retrieval Programme at IAH, Newcastle Gen-
eral Hospital (patients #38–60, Table 1). Retrospec-
tively, the clinical diagnosis in these cases was
compatible with sporadic and/or familial FTLD [4, 23].
Of these 23 patients, 13 (57%) were male, 10 (43%)
were female. Mean age at onset of disease was
59.7 § 17.8 years, and mean duration of illness was
5.2 § 2.9 years. The Manchester patients did not diVer
from the Newcastle patients in terms of gender distri-
bution (2 =0 . 7 5 ,  P = 0.39) or age at onset (t = 0.59,
P = 0.56). However, they had a longer duration of ill-
ness (t =2 . 7 9 ,  P = 0.007). At both Centres, all brains
had been collected in accordance with Local Ethical
Committee approval.
Brains had been Wxed in 10% buVered formalin for a
period of between 1–3 months after which blocks of tis-
sue were cut from frontal (Brodmann areas 8/9), and
(except in patient #38) temporal (Brodmann areas 21/
22) cortex and hippocampus (at the level of the genicu-
late bodies), and processed routinely into paraYn wax.
Sections were cut at a thickness of 5 m. Although
UBQ pathology is also widely present within the stria-
tum in cases of FTLD-U [13], this region was not
always available, and therefore not included in the
present study. Sections of frontal cortex from both
Manchester and Newcastle series, and those of tempo-
ral cortex and hippocampus from the Manchester
series alone, were immunostained for UBQ using an
automated staining procedure [17], using a polyclonal
anti-UBQ antibody (Dako, Glostrup, Denmark,
1:500). Sections of temporal cortex and hippocampus
from the Newcastle series were immunostained in
Newcastle, again using the polyclonal DAKO UBQ
antibody, at the same dilution (1:500).
The UBQ immunostained sections were viewed
by experienced Neuropathologists in Manchester
(DMAM), Newcastle (AB) and Vancouver (IRAM)
and were classiWed into UBQ histological type by con-
sensus according to the form and distribution of UBQ
pathological changes. The severity of UBQ pathology
within each histological type, both as the extent of
neuritic changes or neuronal cytoplasmic inclusions
within layer II of the frontal and the temporal cortex,
or neuronal cytoplasmic inclusions within granule cells
of the dentate gyrus of the hippocampus was rated
semiquantitatively according to (0 = absent; 1 = rare;
2=m i l d ;  3=m o d e r a t e ;  4=s e v e r e ) .  R a t i n g  w a s  p e r -
formed independently by two observers (DMAM and
IRAM), with the UBQ score being averaged where
any disagreement arose. Scores for the extent of neu-
ritic changes and neuronal cytoplasmic inclusions in
frontal and temporal cortex, and neuronal cytoplasmic
inclusions in hippocampus, were then summed to give
an overall cerebral cortical UBQ severity rating
(maximum = 20).
All statistical tests were performed using SSPS 13.0.Acta Neuropathol (2006) 112:539–549 541
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Table 1 Selected clinical, genetic and pathological details of 60 patients with FTLD-U, 37 accessioned in Manchester and 23 in New-
castle
Case UBQ 
phenotype
MAPT 
genotype
Gender Onset 
(years) 
Duration 
(years)
Frontal Temporal Hippo Total 
UBQ 
score
NII Family 
history
Clinical 
diagnosis
neurites incl neurites incl incl
Manchester
1 1 H2H2 F 53 18 4 4 4 4 3 19 Y Y FTD
2 1 n a F 5 1 1 0 4 44 42 1 8 Y Y F T D
3 1 H1H2 M 49 9 3 3 2 1 4 13 Y Y FTD
4 1 H1H1 F 56 10 3 3 1 0 2 9 Y Y FTD
5 1 H1H2 M 60 8 4 4 4 4 4 20 Y Y FTD
6 1 H1H2 M 69 6 4 4 3 2 1 14 Y Y FTD
7 1 H1H2 F 54 13 3 2 4 2 4 11 Y N FTD
8 1 H1H1 F 59 5 3 2 1 1 2 9 Y N FTD
9 1 H1H1 M 55 16 3 4 4 4 0 15 Y Y PNFA
10 1 H2H2 M 62 8 3 2 4 3 1 13 Y Y PNFA
11 1 H1H2 M 68 10 4 3 4 3 3 17 Y Y PNFA
12 1 H1H1 F 63 8 1 1 3 2 4 11 Y Y PNFA
13 1 H1H1 M 66 7 3 4 1 0 1 9 Y Y PNFA
14 1 H1H1 F 61 8 3 2 2 1 3 11 Y N SD
15 2 na M 61 12 1 0 2 1 1 5 N N FTD
16 2 na M 63 8 3 1 0 0 0 4 N N PNFA
17 2 na F 58 5 3 1 na na na na N N SD
18 2 H1H2 M 54 14 3 1 2 0 1 7 N N SD
19 2 H1H1 F 55 11 4 2 3 1 3 13 N N SD
20 2 H1H1 M 60 15 2 1 2 1 0 6 N N SD
21 2 H1H2 F 56 11 3 1 1 1 3 9 N N SD
22 2 H1H1 F 70 2 3 1 4 2 4 14 N N SD
23 2 H1H2 M 71 6 1 1 3 1 4 10 N N SD
24 3a H1H2 M 60 8 0 4 0 3 0 7 N N FTD
25 3a na M 45 2 1 4 1 4 4 16 N N FTD + MND
26 3a H1H1 M 43 2 1 4 1 3 4 13 N N FTD + MND
27 3a H1H1 M 57 2 1 1 1 1 3 7 N N FTD + MND
28 3a H1H2 F 50 3 1 3 1 4 4 13 N Y FTD + MND
29 3a H1H2 M 62 14 3 4 3 4 2 16 N N PNFA
30 3b H1H1 M 45 4 1 1 0 0 4 6 N N FTD
31 3b H1H2 M 46 4 1 0 1 2 2 6 N N FTD
32 3b H1H2 M 45 6 1 1 1 1 4 8 N N FTD
33 3b H1H2 M 59 7 1 0 1 0 3 5 N N FTD
34 3b H1H2 M 58 8 1 0 2 1 1 5 N N FTD
35 3b H1H2 M 68 6 1 0 1 1 2 5 N Y FTD
36 3b H1H1 M 65 2 1 2 0 0 3 6 N N FTD + MND
37 3b H1H1 M 58 11 1 0 2 0 3 6 N N FTD + MND
Newcastle
38 1 H1H1 F 72 2 4 4 3 1 1 13 Y na *
39 1 H1H2 M 65 6 3 4 3 1 3 14 Y N *
40 1 H1H2 M 75 2 2 2 1 1 0 6 Y N *
41 1 H1H1 M 74 5 1 0 1 0 1 3 N na *
42 1 H1H2 M 65 8 2 2 2 2 1 11 N ?Y *
43 2 H1H1 F 62 7 4 2 2 1 1 10 N Y *
44 2 H1H1 M 59 6 2 0 3 1 2 8 N na *
45 2 H1H1 M na na 2 1 2 1 1 7 N na *
46 2 H1H1 M 21 8 1 0 0 0 0 1 N na *
47 2 H1H1 F 72 3 3 2 2 0 2 9 N Y *
48 2 H1H1 F na na 1 0 2 0 2 5 N na *
49 2 H1H1 F 80 5 2 0 2 3 1 7 N N *
50 3a H1H1 F 40 6 0 4 0 1 2 7 N N *
51 3a na F 35 8 0 0 0 1 0 1 N na *
52 3a na M 43 2 1 2 2 2 2 9 N N *
53 3a na M 82 5 1 0 0 1 0 2 N na *
54 3a H1H2 M 59 14 1 0 0 1 1 3 N na *
55 3b na F 33 4 0 1 0 1 0 2 N na *
56 3a H1H1 M 59 4 2 1 1 2 3 9 N na *542 Acta Neuropathol (2006) 112:539–549
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Results
Histological phenotypes
On the basis of appearance in UBQ immunostained
sections, three histological phenotypes were discerned:
Type 1: This was present in 19 patients (32%)
(patients #1–14 and #38–42) . In these, there was a
moderate number, or numerous, UBQ immunoreac-
tive neurites and intraneuronal cytoplasmic inclusions
within layer II of the cerebral cortex (Fig.  1a, Table 1).
Cytoplasmic inclusions within granule cells of the den-
tate gyrus were variable, ranging from a few to many
(Fig.   1b, Table 1). Neuronal intranuclear inclusions
(NII) of a “cat’s eye” or “lentiform” appearance [16,
32] were present in 17 of these patients (Fig.  1c,
Table 1). These were never very numerous in any
patient, ranging from about ten per section (of frontal
or temporal cortex) in some patients down to only a
single NII in others. Only in a single patient (patient
#2) was a single NII seen within dentate gyrus granule
cells (Fig. 1d), and in another patient (patient #3) NII
were seen within two pyramidal cells in area CA4 of
hippocampus (one shown in Fig. 1e).
Type 2: This was present in 16 patients (27%)
(patients #15–23 and #43–49). In these, UBQ neurites
were predominantly, or exclusively, present within
layer II of the cerebral cortex with few or no intraneu-
ronal cytoplasmic inclusions (Fig. 2a, Table 1). Cyto-
plasmic inclusions within granule cells of the dentate
gyrus were variable, being few or absent in eight
patients, moderate in three patients, but numerous in
four others (Fig. 2b, Table 1); the hippocampus was
not available for investigation in the other case. NII
were not present in any of these 16 patients.
Type 3: In the remaining 25 patients (42%) (patients
#24–37 and #50–60), UBQ neuronal cytoplasmic inclu-
sions were predominantly, or exclusively, present
within the brain with only relatively few UBQ neurites
being present. Two subtypes were identiWed. In 12
patients, with type 3a histology (patients #24–29 and
#50–55), UBQ inclusions were numerous within neuro-
nes of layer II of the frontal and temporal cortex
(Fig. 3a, Table 1), but only in 6 of these patients were
cytoplasmic inclusions within granule cells of the den-
tate gyrus numerous (Fig. 3b, Table 1). In the other 13
patients, with type 3b histology (patients #30–37 and
#56–60), UBQ cytoplasmic inclusions within granule
cells of the dentate gyrus was the major pathology
(Fig. 3c, Table 1), with relatively few or no neuronal
cytoplasmic inclusions (and neurites) being present
within the cerebral cortex (Fig. 3d). Again, NII were
not present in any patient.
Patients with type 2 histology were clearly diVerenti-
ated from those with type 1 histology according to the
relative balance between UBQ neuronal cytoplasmic
inclusions and UBQ neurites within the cerebral cor-
tex. The presence of NII per se did not act as a sine qua
non for type 1 histology (two patients with type 1 his-
tology did not show NII), nor did the number or pres-
ence of hippocampal cytoplasmic inclusions inXuence
such diVerentiation. In type 1 histology, UBQ neuronal
cytoplasmic inclusions and neurites were both numer-
ous within layer II of the cerebral cortex, whereas in
type 2 histology the overwhelming preponderance of
UBQ neuritic pathology relative to UBQ neuronal
inclusions was the deciding factor. The presence of
numerous UBQ neuronal inclusions either within the
cerebral cortex or the hippocampus (or both) in the
relative or total absence of a UBQ neuritic pathology
marked type 3 histology from that of either type 1 or
type 2 histology.
The mean total UBQ score was signiWcantly greater
(F2,56=1 2 . 3 ,  P < 0.001) in cases with type 1 histology
(12.5 § 4.2) than for cases with type 2 (7.6 § 3.4) or
type 3 ( i.e. with 3a and 3b type histologies combined)
(6.6 § 4.2), which did not diVer from each other.
Demographics
Of the 19 patients with type 1 UBQ histology, 11
(58%) were male and 8 (42%) were female. Mean age
Table 1 continued
UBQ ubiquitin, MAPT tau gene, Frontal frontal cortex, Temporal temporal cortex, Hippo hippocampus, incl inclusions, NII neuronal
nuclear inclusions, M male, F female, Y yes, N no, FTD frontotemporal dementia, SD semantic dementia, PNFA progressive non-Xuent
aphasia, MND Motor neurone disease, * retrospective clinical diagnosis compatible with FTLD, na data not available
Case UBQ 
phenotype
MAPT 
genotype
Gender Onset 
(years) 
Duration
(years)
Frontal Temporal Hippo Total 
UBQ 
score
NII Family 
history
Clinical 
diagnosis
neurites incl neurites incl incl
57 3b H1H2 M 63 1 0 0 1 0 1 2 N na *
58 3b H1H1 M 68 3 1 0 1 0 2 4 N na *
5 9 3 b n aF4 0 6 00 00 3 3 N n a *
6 0 3 b n aF8 6 4 02 10 2 5 N n a *Acta Neuropathol (2006) 112:539–549 543
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at onset of disease was 62.0 § 7.7 years and mean dura-
tion of disease was 8.4 § 4.1 years. Of the 16 patients
with type 2 UBQ histology, 8 (50%) were male and 8
(50%) were female. Mean age at onset of disease was
60.1 § 13.5 years and mean duration of disease was
8.1 § 4.0 years in those 14/16 patients where this infor-
mation was available. Of the 25 patients with type 3
UBQ histology, 19 (76%) were male and 6 (24%) were
female. Mean age at onset of disease was 54.8 § 13.5
years and mean duration of disease was 5.4 § 3.5 years.
The preponderance of males compared to females
associated with type 3 histology was statistically signiW-
cant (binomial test, P = 0.015). Male to female ratios
did not diVer signiWcantly for other histological types.
Numerical diVerences in age at onset of cases with each
of the three histological phenotypes did not reach sta-
tistical signiWcance (F2,55= 2.16, P = 0.13). However,
there was a signiWcant eVect of histological type on
duration of illness (F2,55= 3.83, P = 0.03). Post-hoc
Bonferroni tests showed that cases with type 3 histol-
ogy had a signiWcantly shorter duration than cases with
type 1 histology (P =0 . 0 4 ) .
Relationship to clinical phenotype
Although, retrospectively the Newcastle cases had a
clinical diagnosis compatible with FTLD, these cases
had not been prospectively assessed with the primary
purpose of characterising the neuropsychological deW-
cit. It was therefore only possible to examine relation-
ships with clinical subtype within the Manchester series
of 37 cases. Eight of 14 patients with type 1 histology
had clinical FTD, 5 had PNFA and 1 SD. One of nine
patients with type 2 histology had FTD, one had PNFA
but seven had SD. Seven of 14 patients with type 3 his-
tology had FTD, 6 had FTD + MND and 1 had PNFA.
Putting it another way, eight of eleven patients with
FTD had type 1 histology and three had type 3 histol-
ogy. Five of seven patients with PNFA had type 1 his-
tology and one each had types 2 and 3 histology. Seven
of eight patients with SD had type 2 histology and one
had type 1 histology. All 6 patients with FTD + MND
had type 3 histology. Hence, type 1 pathology was
mostly associated with cases of FTD or PNFA,
whereas type 2 histology tended to be associated
Fig. 1 Type 1 histology: In 
patient #1 there are numer-
ous, UBQ immunoreactive 
neurites and intraneuronal 
cytoplasmic inclusions within 
layer II of the cerebral cortex 
(a) though UBQ cytoplasmic 
inclusions within granule cells 
of the dentate gyrus were rela-
tively few (b). Neuronal intra-
nuclear inclusions (NII) of a 
“cat’s eye” or “lentiform” 
appearance were also seen in 
pyramidal cells of layer II of 
cerebral cortex in this patient 
(c). Only in a single patient 
(patient #2) was a single NII 
seen within hippocampus den-
tate gyrus granule cells (d), 
and in another patient (pa-
tient #3) NII were seen within 
pyramidal cells in area CA4/5 
of hippocampus (e). Immun-
operoxidase-haematoxylin, 
£20 (a), £40 (b–e) micro-
scope magniWcation544 Acta Neuropathol (2006) 112:539–549
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mostly with cases of SD, and type 3 pathology with
cases of FTD or FTD + MND. The inXuence of histo-
logical type on clinical phenotype was highly signiWcant
(2 =3 3 . 7 ,   P < 0.0001)
Relationship to genotype
MAPT haplotype and genotype data was available
for 32/37 Manchester patients and 17/23 Newcastle
Fig. 2 Type 2 histology: In 
patients #22 and #19, there are 
numerous UBQ neurites pre-
dominantly, or exclusively, 
present within layer II of the 
cerebral cortex with few or no 
intraneuronal cytoplasmic 
inclusions (a and c, respec-
tively). UBQ cytoplasmic 
inclusions within granule cells 
of the dentate gyrus were also 
numerous in patient #22 (b), 
but were less common in 
patient #19 (d) Immunoper-
oxidase-haematoxylin, £20 
(a, c), £40 (b, d) microscope 
magniWcation
Fig. 3 Type 3 histology: In 
patient #28 with type 3a histol-
ogy, UBQ neuronal cytoplas-
mic inclusions are 
predominantly, or exclusively, 
present within the brain with 
only relatively few UBQ neu-
rites being present (a). UBQ 
inclusions were also some-
times numerous within gran-
ule cells of the dentate gyrus 
numerous (b). In patient #32 
there were few neuronal UBQ 
cytoplasmic inclusions and 
neurites within the cerebral 
cortex (c), though UBQ cyto-
plasmic inclusions were wide-
spread within granule cells of 
the hippocampus dentate gy-
rus (d). Immunoperoxidase-
haematoxylin, £20 (a, c), 
£40 (b, d) microscope 
magniWcationActa Neuropathol (2006) 112:539–549 545
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patients.  MAPT haplotype frequency did not diVer
across any of the three histological groups (Table 2).
There was no overall inXuence of histological type on
genotype frequency (2 = 3.98, P = 0.14). However, the
comparison of histological types 2 and 3 alone reached
statistical signiWcance (2 =3 . 8 3 ,  P = 0.05), suggesting
that H1H1 genotype was more likely to be associated
with type 2 histology and H1H2 with type 3 histology.
More importantly, however, when combining all three
histological groups, total UBQ score tended to increase
(F2,46 = 56.7,  P = 0.047) with possession of MAPT H2
haplotype in a dose-dependent way (H1H1 = 8.4 § 3.5,
H1H2 = 9.6 § 4.9, H2H2 = 16.0 § 4.2).
Discussion
In recent times there have been numerous investiga-
tions [2, 6, 10, 17, 20, 28, 30] indicating that a tau-nega-
tive, ubiquitin-positive pathology, known as FTLD-U,
is a frequent, if not the most common, histological
change underlying FTLD. Nonetheless, in most stud-
ies [2,  6,  10–12,  14,  15,  17,  20,  28,  30], little or no
attempt has been made to diVerentiate cases according
to the phenotypic appearance of the UBQ changes,
with all cases being simply referred to as FTLD-U.
Only in one previous study [13] did the authors corre-
late the appearance of the ubiquitin pathology with
clinical phenotype, but then mainly from the perspec-
tive of diVerentiating between cases of FTD with or
without accompanying MND. In this latter study, this
was done according to diVerences in the density and
morphology of UBQ changes in the cerebral cortex,
hippocampus and striatum [13]. In the present study,
we have classiWed 60 cases of FTLD-U drawn from
two UK Centres (Manchester and Newcastle) into
three distinct histological subtypes according to the
appearance and anatomical distribution of the UBQ
pathology within the cerebral cortex and hippocam-
pus. We have been able to extend previous observa-
tions [13] and show that clinical representations of
FTLD other than FTD + MND (i.e. FTD, SD and
PNFA) are strongly associated with each of the diVer-
ent histological subtypes. The results of our study may
have important nosological implications for the classi-
Wcation of FTLD.
The histological subtype we have designated as type
1 is characterised by many UBQ immunoreactive neu-
rites, and UBQ intraneuronal cytoplasmic inclusions
with “cat’s eye” or “lentiform” NII, within layer II of
the cerebral cortex, and variable numbers of UBQ
cytoplasmic inclusions within granule cells of the den-
tate gyrus. Nineteen patients (32%) showed type 1 his-
tology, 17 with NII. This type of histology was typically
seen in patients with clinical FTD or PNFA. On the
basis of their examinations of UBQ immunostained
sections of cerebral cortex, hippocampus and striatum,
Katsuse and Dickson [13] described one form of UBQ
pathology, which they termed FTLD-MNI (FTLD with
motor-neuron disease (MND)-type inclusions but
without MND) in 47/52 patients with FTLD-U and
another form which they called FTLD-MND (FTLD
with MND). Although here we did not examine the
striatum, their descriptions of FTLD-MNI and FTLD-
MND [13] bear close resemblance to those which we
have termed type 1 and type 3 histology, respectively.
Nonetheless, in contrast to present Wndings, where NII
were universal in type 1 cases, these were reported by
Katsuse and Dickson to occur in only 26 of their
FTLD-MNI cases [13]. It is possible that selection cri-
teria account for these diVerences. In the present study,
we diVerentiated cases of type 1 histology from those
with type 2 histology (see above for criteria) in whom
NII were not seen, whereas in the study by Katsuse and
Dickson [13], because they did not attempt to further
subtype their FTLD-MNI cases, it is possible that these
could have included cases of (our) type 2 histology in
whom NII would not have been anticipated.
In the present study, type 2 histology, with abundant
UBQ neurites but few or no cytoplasmic inclusions
or NII, was the most common histology present in
patients with SD-8/9 Manchester patients with SD
showed type 2 histology and 8/9 patients with type 2
histology had SD. FTLD-U had been previously
reported by Rossor et al [26] to be the underlying his-
tology in three patients with SD, and from the histolog-
ical descriptions provided it would appear that these
three patients also displayed UBQ pathological changes
similar to type 2 histology described here, although this
was not so remarked upon at the time.
Type 3 histology, characterised by numerous neuro-
nal UBQ cytoplasmic inclusions but few or no UBQ
neurites was seen in all six Manchester patients with
FTD + MND. Although others [3, 13] have suggested
that the type 1 histology may be present in some cases
Table 2 MAPT genotype and haplotype frequencies in FTLD-U
according to the diVerent histological subtypes. Numbers of cases
with each genotype or haplotype are shown with percentage fre-
quencies given in parentheses
Ubiquitin 
phenotype
MAPT genotype MAPT haplotype
H1H1 H1H2 H2H2 H1 H2
1 8 (44) 8 (44) 2 (12) 24 (66) 12 (34)
2 10 (77) 3 (23) 0 (0) 23 (88) 3 (12)
3 7 (41) 10 (59) 0 (0) 24 (71) 10 (29)546 Acta Neuropathol (2006) 112:539–549
123
of FTD + MND, in the present series such cases were
not encountered. However, it is accepted that the small
numbers of such patients studied here may have
precluded the Wnding of cases with alternative UBQ
histologies. In four of these (patients# 25–28) both
cerebral cortical and hippocampal neurones were
extensively involved, though in the other two (patients
#36 and 37) only hippocampal neurones were severely
aVected. However, there were eight other patients
with this type of histology, albeit in most instances
restricted to hippocampus, none of whom showed any
clinical or pathological evidence of MND. Seven of
these patients had FTD alone and one had PNFA,
emphasising the overlapping pathology between FTD
and FTD + MND, particularly as far as the hippocam-
pus is concerned [31].
When we compared duration of illness across the his-
tological phenotypes we found that it was shorter in
patients with type 3 histology than in other patients.
These Wndings are most likely explained by the inclu-
sion of those patients with FTD + MND within this his-
tological subtype, for whom a shorter duration of illness
has been previously reported [6,  10,  12,  22]. In such
individuals it is likely that the disease is terminated
early through the presence of bulbar muscle wasting
and respiratory failure consequent upon MND.
What we have presently termed type 1 histology
occurs in certain families with autosomal dominant
transmission of disease known to be linked to chromo-
some 17q21 [8,  18,  24,  25] .  R e c e n t  w o r k  [ 1,  6] has
shown that FTLD in many of these latter families is
caused by mutations in progranulin gene (PGRN),
located just 1.8 mb distant from MAPT locus on chro-
mosome 17q21. Such observations raise the possibility
that type 1 histology, and perhaps the NII component
thereof, might act as a surrogate marker of PGRN
mutation-related FTLD. This argument is supported
by several observations.
Firstly, that two of the present patients with FTLD
reported in Baker et al. [1], one with Q130SfsX124 muta-
tion and one with Q468Xmutation (patients #4 and #12,
respectively in the present study), in whom the disease
was not previously known to be linked to chromosome
17, did indeed have this pathology. Since then we have
further found in patient #13 the C31LfsX34 mutation
reported initially in a Canadian family UBC-17 with
chromosome 17-linked tau negative histology and pub-
lished in Baker et al. [1], and a novel PGRN mutation
(V452WfsX38) in patient #7 (Pickering-Brown, unpub-
lished data), both with type 1 histology. We are contin-
uing to analyse the remaining ten patients with this
histological subtype for PGRN mutations to provide
further support for this viewpoint. Furthermore, since the
original studies by Baker et al. [1] and Cruts et al. [6],
many other additional FTLD-U cases with PGRN
mutations have also been identiWed by other workers,
and NII were present in all cases where post mortem
brain analysis had been done (Mackenzie–manuscript
submitted).
Secondly, none of the 16 patients with type 2 histol-
ogy showed NII, even though there was positive family
history of FTLD in two of these (patients #43 and #47).
So far, we have not detected PGRN mutation in any of
these 16 patients, nor have we found any such muta-
tions in a further 25 clinically conWrmed living patients
with SD (most of whom can be presumed to have type
2 histology) (Pickering-Brown, unpublished data), sug-
gesting PGRN mutations are unlikely to underpin this
form of UBQ pathology. Nonetheless, paradoxically,
patient #14 with SD did in fact show type 1 histology
and had a positive family history; PGRN analysis in
this patient has not as yet revealed PGRN mutation
(Pickering-Brown, unpublished data).
Thirdly, NII were not present in any patient with
type 3 histology, including the six patients with
FTD + MND. Similarly, although Katsuse and Dickson
[13] reported NII to be present in 26/43 cases of FTLD-
U, none of their cases had clinical and pathological
MND. However, in another study of 34 patients with
FTLD-U, 11 patients showed NII of whom 3 had FTD
and clinical and pathological MND [3]. It is not known
in either of these latter studies whether any or all such
cases with NII bore PGRN mutation. We have so far
been unable to detect PGRN mutation in any of the
present 6 clinically and pathologically conWrmed cases
of FTD + MND, nor have we found any such muta-
tions in a further 22 clinically conWrmed living patients
with FTD + MND and presumed type 3 histology (Pic-
kering-Brown, unpublished data).
However, the Wnding of ubiquitinated NII in
patients with Inclusion Body Myopathy with Pagets
Disease of bone and FTD (IBMPFD) associated with
mutations in the valosin-containing protein gene
(VCP) [7, 26] apparently similar to those seen in FTLD
would argue against speciWcity of UBQ NII in FTLD as
markers of PGRN mutations. However, although NII
in VCP mutations contain VCP protein [7, 26] and may
superWcially resemble those in FTLD cases with PGRN
mutation, the latter do not contain VCP protein [28].
Moreover, IBMPFD is an extremely rare disorder, and
can be readily distinguished from FTLD both clinically
and pathologically, in terms of the nature and distribu-
tion of UBQ pathology [7]. Hence, patients with “cat’s
eye” NII, within the context of clinical FTD not associ-
ated with muscle or bone abnormality, are unlikely to
possess VCP mutation.Acta Neuropathol (2006) 112:539–549 547
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Furthermore, NII in FTLD are not always observed
in the context of a previous positive family history.
Although in the present study linkage analysis had not
been performed, 15/17 patients with NII had shown
positive family history consistent with autosomal domi-
nance. Nonetheless, two patients showed no previous
family history, and the presence of NII in apparently
sporadic cases has been noted by others [3, 13]. On face
value, such observations would again argue against NII
being pathognomic for PGRN mutations, though in at
least some cases included in the latter studies [3, 13]
PGRN mutations have in fact now been found (Mac-
kenzie, personal communication). Hence, whether
there are indeed sporadic FTLD-U cases with NII but
without PGRN mutations must remain an open ques-
tion until all such potential cases have undergone
genetic analysis and the absence of such a mutation
deWnitely ruled out.
Hence, current data would strongly suggest that the
presence of NII in FTLD is indicative of PGRN muta-
tion, though this conclusion must remain tentative until
all cases with these pathological structures, both within
this present study and in those of other research
groups, have been subjected to genetic analysis and the
presence or absence of mutation deWned. Nonetheless,
should this relationship between NII and PGRN muta-
tions turn out to be correct, then present data showing
type 1 histology to be present in 17/60 patients with
FTLD-U in the Manchester and Newcastle combined
series (present in 14/37 Manchester patients with
FTLD-U, and in 14/73 Manchester patients with FTLD
per se) would suggest that PGRN mutations are a more
common cause of (inherited) FTLD than those with
MAPT mutations, outnumbering the latter by a factor
of 2:1 (only 8/73 Manchester patients with FTLD had
MAPT mutations [17, 28]).
Interestingly, a number of FTLD clinical pheno-
types were embraced by type 1 histology, but princi-
pally FTD and PNFA. Indeed, patients #4 and #7 with
Q468X and V452WfsX38 mutation, respectively, dis-
played FTD phenotype, whereas patients #12 and #13
with Q130Sfx124 and C31LfsX34 mutations showed
PNFA. Such observations argue that although type 1
histology might be associated per se with PGRN muta-
tions (vide supra) the brain topographic distribution of
that form of UBQ pathology may depend upon factors
other than the actual mutation, since it has been pro-
posed that all PGRN mutations induce the same patho-
physiological haploinsuYciency through the creation
of a null allele [1, 6].
Finally, although none of the cases studied here
were associated with MAPT mutations, there appeared
to be variations in frequency of MAPT haplotypes and
genotypes between the diVerent histological subtypes.
For example, type 2 histology was associated with a sig-
niWcantly higher H1H1 frequency (but not H1 haplo-
type frequency), and type 3 histology with H1H2
genotype. By contrast, the extent of UBQ pathology
(irrespective of histological subtype) increased with
possession of H2 allele. Such observations suggest
MAPT haplotype might play a part in modulation of
the overall degree of UBQ pathology and/or the histo-
logical form manifested. However, these observations
are based on small sample sizes, especially those relat-
ing to H2 allele, and will require validation in further,
and larger, cohorts before they can be considered to be
substantive.
What the ubiquitinated protein present within the
neuronal cytoplasmic inclusions, NII and neurites
might be remains unknown. Indeed, it is not clear
whether it is actually the same protein that is accumu-
lated at all three anatomical sites, or diVerent site spe-
ciWc proteins. Certainly, the protein does not appear to
be progranulin, since antibodies to this do not immu-
nolabel any of the ubiquitinated structures present in
patients with either chromosome-17 linked FTLD with
PGRN mutations [1], or in patients within the present
series with type 1 histology and PGRN mutations
(where known), or in others with types 2 and 3 histol-
ogy (Mann, unpublished data).
In conclusion, in this present study, we have
described three distinct histological proWles that
encompass the pathological entity of FTLD-U. We
have been able to show that the various clinical repre-
sentations of FTLD are strongly associated with each
of the diVerent histological subtypes. Each of these
subtypes may have separate underlying pathophysio-
logical causes which might reXect (1) diVerent ubiquiti-
nated proteins accumulating, (2) diVerent forms of the
same protein, or (3) diVerent anatomical distributions
of an identical protein, within each histological sub-
type. By reWning our histological criteria of FTLD-U it
might be possible to better determine genetic or other
factors which cause or increase the risk of developing
the diVerent clinical or pathological forms of FTLD.
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